Header

UZH-Logo

Maintenance Infos

Developments in targeted therapy in melanoma


Amann, V C; Ramelyte, E; Thurneysen, S; Pitocco, R; Bentele-Jaberg, N; Goldinger, S M; Dummer, R; Mangana, J (2017). Developments in targeted therapy in melanoma. European Journal of Surgical Oncology, 43(3):581-593.

Abstract

Melanomas are disease entities driven in part by the mitogen activated protein kinase (MAPK) pathway. The TCGA network recently defined four genetic subtypes based on the most prevalent significantly mutated genes, including mutant BRAF, mutant RAS (N/H/K), mutant NF1, and Triple wild-type melanoma (harboring none of the aforementioned mutations, but instead includes KIT, GNA and GNAQ mutations). The successful development of kinase inhibitors marked a milestone in the treatment of metastatic melanoma. Combination treatment with a BRAF- and MEK-inhibitor is the current standard of care for inoperable stage IIIC/IV BRAF-mutated melanoma. Recent data demonstrate excellent long-term outcome, especially in patients with normal baseline LDH levels, and confirm that there is a subset of BRAF inhibitor-naive patients who experience durable responses without progression on combination treatment. In the future, adding a third compound based on individual genetic alterations might further improve the outcome of targeted therapy.

Abstract

Melanomas are disease entities driven in part by the mitogen activated protein kinase (MAPK) pathway. The TCGA network recently defined four genetic subtypes based on the most prevalent significantly mutated genes, including mutant BRAF, mutant RAS (N/H/K), mutant NF1, and Triple wild-type melanoma (harboring none of the aforementioned mutations, but instead includes KIT, GNA and GNAQ mutations). The successful development of kinase inhibitors marked a milestone in the treatment of metastatic melanoma. Combination treatment with a BRAF- and MEK-inhibitor is the current standard of care for inoperable stage IIIC/IV BRAF-mutated melanoma. Recent data demonstrate excellent long-term outcome, especially in patients with normal baseline LDH levels, and confirm that there is a subset of BRAF inhibitor-naive patients who experience durable responses without progression on combination treatment. In the future, adding a third compound based on individual genetic alterations might further improve the outcome of targeted therapy.

Statistics

Citations

Dimensions.ai Metrics
6 citations in Web of Science®
8 citations in Scopus®
12 citations in Microsoft Academic
Google Scholar™

Altmetrics

Downloads

48 downloads since deposited on 08 Dec 2016
47 downloads since 12 months
Detailed statistics

Additional indexing

Item Type:Journal Article, refereed, further contribution
Communities & Collections:04 Faculty of Medicine > University Hospital Zurich > Dermatology Clinic
Dewey Decimal Classification:610 Medicine & health
Language:English
Date:2017
Deposited On:08 Dec 2016 14:01
Last Modified:19 Feb 2018 07:27
Publisher:Elsevier
ISSN:0748-7983
OA Status:Green
Publisher DOI:https://doi.org/10.1016/j.ejso.2016.10.014
PubMed ID:27923592

Download

Download PDF  'Developments in targeted therapy in melanoma'.
Preview
Content: Accepted Version
Filetype: PDF
Size: 722kB
View at publisher